Vor Biopharma (VOR) Income from Non-Controlling Interests (2022 - 2026)
Vor Biopharma's (VOR) quarterly Income from Non-Controlling Interests came in at -$747000.0 in Q1 2026, down 74800.0% year-on-year from N/an in Q1 2025, and down 2675.86% on a QoQ basis from $29000.0 in Q4 2025.
Vor Biopharma (VOR) Income from Non-Controlling Interests (2022 - 2026) Analysis & Trends
Vor Biopharma (VOR) has 5 years of Income from Non-Controlling Interests data on file, last reported at -$747000.0 in Q1 2026.
- On a quarterly basis, Income from Non-Controlling Interests fell 74800.0% year-over-year to -$747000.0 in Q1 2026; TTM through Mar 2026 was -$729000.0, a 762.73% decrease from a year earlier, with the FY2025 full-year figure at $19000.0, down 80.81% from the prior year.
- Income from Non-Controlling Interests for Q1 2026 stood at -$747000.0, down from $29000.0 in the prior quarter.
- Over the last five years, Income from Non-Controlling Interests for VOR reached as high as $596000.0 in Q1 2023 and fell as low as -$1.1 million in Q1 2022.
- Historically, Income from Non-Controlling Interests has averaged -$41529.4 across 5 years, with a median of $1000.0 in 2025.
- Across the five-year window, Income from Non-Controlling Interests soared 163.04% in 2025 and tumbled 74800.0% in 2026, its largest moves.
- Year by year, Income from Non-Controlling Interests stood at $408000.0 in 2022, then sank by 50.25% to $203000.0 in 2023, then slumped by 122.66% to -$46000.0 in 2024, then jumped by 163.04% to $29000.0 in 2025, then plunged by 2675.86% to -$747000.0 in 2026.
- Per Business Quant data, the three most recent Income from Non-Controlling Interests figures were -$747000.0 in Q1 2026, $29000.0 in Q4 2025, and -$2000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Vor Biopharma | 187.37 Mn | 187.37 Mn | - | -747,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -747,000.00 |
| Dec 31, 2025 | 29,000.00 |
| Sep 30, 2025 | -2,000.00 |
| Jun 30, 2025 | -9,000.00 |
| Mar 31, 2025 | 1,000.00 |
| Dec 31, 2024 | -46,000.00 |
| Sep 30, 2024 | 138,000.00 |
| Jun 30, 2024 | 17,000.00 |
| Mar 31, 2024 | -10,000.00 |
| Dec 31, 2023 | 203,000.00 |
| Sep 30, 2023 | 156,000.00 |
| Jun 30, 2023 | -262,000.00 |
| Mar 31, 2023 | 596,000.00 |
| Dec 31, 2022 | 408,000.00 |
| Sep 30, 2022 | 148,000.00 |
| Jun 30, 2022 | -254,000.00 |
| Mar 31, 2022 | -1.07 Mn |